SABR for metastasis-directed therapy — what we’ve learned and what’s to come

Nature Reviews Clinical Oncology, Published online: 22 July 2020; doi:10.1038/s41571-020-0416-9SABR-COMET was the first randomized controlled trial to demonstrate an overall survival benefit with the use of stereotactic ablative body radiotherapy (SABR) for the treatment of oligometastatic cancer. Considering the recently reported long-term follow-up data from SABR-COMET, we review the outcomes and limitations of this study in the context of other emerging information on therapy for oligometastatic disease.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research